Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 439

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson

Blood (2021) 138 (13): 1089.

https://doi.org/10.1182/blood.2021012674

Published: 2021

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Blood (2021) 138 (7): 544–556.

https://doi.org/10.1182/blood.2020009165

Published: 2021

Includes: Supplemental data

Journal Articles

CLL cells are moved by the MARCKS brothers

Jan A. Burger

Blood (2021) 138 (7): 503–504.

https://doi.org/10.1182/blood.2021011650

Published: 2021

Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Blood (2021) 138 (1): 44–56.

https://doi.org/10.1182/blood.2020006765

Published: 2021

Includes: Supplemental data

Journal Articles

Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912-1915.

Blood (2021) 137 (11): 1561.

https://doi.org/10.1182/blood.2021010938

Published: 2021

Journal Articles

Occupy BTK: the key to controlling CLL

Philip A. Thompson

Blood (2020) 136 (1): 4–6.

https://doi.org/10.1182/blood.2020005877

Published: 2020

Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Blood (2020) 136 (1): 93–105.

https://doi.org/10.1182/blood.2019003715

Published: 2020

Includes: Supplemental data

Journal Articles

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Piers Blombery, Tamia Nguyen, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Mary Ann Anderson

Blood (2020) 135 (25): 2266–2270.

https://doi.org/10.1182/blood.2020004782

Published: 2020

Includes: Supplemental data

Journal Articles

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Fabienne Lucas, Karylin Larkin, C. Thomas Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gulcin Ozer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen A. Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly

Blood (2020) 135 (24): 2192–2195.

https://doi.org/10.1182/blood.2019003722

Published: 2020

Includes: Supplemental data

Journal Articles

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Steven P. Treon, Jorge J. Castillo, Alan P. Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang

Blood (2020) 135 (21): 1912–1915.

https://doi.org/10.1182/blood.2020006288

Published: 2020

Journal Articles

How I treat Waldenström macroglobulinemia

Meletios A. Dimopoulos, Efstathios Kastritis

Blood (2019) 134 (23): 2022–2035.

https://doi.org/10.1182/blood.2019000725

Published: 2019

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma

Kristen M Rosenthal, PhD, Stephen M Ansell, MD PhD, John P. Leonard, MD, Julie M Vose, MDMBA, Michael L. Wang, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Christopher R. Flowers, MD MS

Blood (2019) 134 (Supplement_1): 410.

https://doi.org/10.1182/blood-2019-124519

Published: 2019

Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD

Blood (2019) 134 (Supplement_1): 478.

https://doi.org/10.1182/blood-2019-124362

Published: 2019

Journal Articles

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Katharine L Lewis, FRCPath, MRCP, MBBS, Kate Manos, MBBS, John Casey, FRACP,FRCPA,MBBS, Julie Crawford, MDMBBS,FRACP, Shir-Jing Ho, FRACP,FRCPA,MBBS, Samar Issa, FRACP, Andrew Grigg, Peter Wood, Maher K. Gandhi, PhD, Eliza A Hawkes, Chan Y. Cheah

Blood (2019) 134 (Supplement_1): 1620.

https://doi.org/10.1182/blood-2019-125730

Published: 2019

NARROW

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

MARCKS affects cell motility and response to BTK inhibitors in CLL

CLL cells are moved by the MARCKS brothers

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912-1915.

Occupy BTK: the key to controlling CLL

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

How I treat Waldenström macroglobulinemia

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only